024 Pharma, Inc. (EEIG) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2016

024 Pharma, Inc.

CIK: 1307969 Ticker: EEIG
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2016
Oct. 20, 2017
Mar. 24, 2017
Document And Entity Information   
Entity Registrant Name024 Pharma, Inc.  
Entity Central Index Key0001307969  
Document Type10-K  
Document Period End DateDec. 31, 2016  
Amendment Flagfalse  
Current Fiscal Year End Date--12-31  
Is Entity a Well-known Seasoned Issuer?No  
Is Entity a Voluntary Filer?Yes  
Is Entity's Reporting Status Current?No  
Entity Filer CategorySmaller Reporting Company  
Entity Public Float  $ 0
Entity Common Stock, Shares Outstanding 336,354,321 
Document Fiscal Period FocusFY  
Document Fiscal Year Focus2016  

View differences made from one year to another to evaluate 024 Pharma, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by 024 Pharma, Inc..


Assess how 024 Pharma, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

024 Pharma, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

024 Pharma, Inc. provided additional information to their SEC Filing as exhibits

Ticker: EEIG
CIK: 1307969
Form Type: 10-K Annual Report
Accession Number: 0001683168-17-000653
Submitted to the SEC: Fri Mar 24 2017 10:39:53 AM EST
Accepted by the SEC: Fri Mar 24 2017
Period: Saturday, December 31, 2016
Industry: Plastics Products

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: